T-cell redirecting bispecific antibodies (BsAbs) and chimeric antigen receptor T cells (CAR T
cells) have revolutionised multiple myeloma therapy, but adverse events such as cytokine …

Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple
myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell …

Background Patients with relapsed/refractory multiple myeloma are at increased risk of
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …

Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory
multiple myeloma (MM) have been poor because of a dearth of effective treatment options …

Multiple myeloma remains an incurable disease, despite the development of numerous drug
classes and combinations that have contributed to improved overall survival …

Chimeric antigen receptor T (CAR T) cell and bispecific antibody therapies have shown
unprecedented efficacy in heavily pretreated patients with multiple myeloma (MM). However …

Abstract Objectives Bispecific antibodies (BsAbs) are an effective treatment used in relapsed
or refractory multiple myeloma. Despite a well-tolerated safety profile, infectious events …

Simple Summary Multiple myeloma, a cancer of the bone marrow, is the commonest cancer
of adults in the Western World. Therapies have advanced dramatically in recent years …

The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal
antibodies like daratumumab along with proteasome inhibitors (PI) s, and immune …

Methods All MM patients who received BsAb therapy on a range of clinical trials between 1st
January 2018 and 30th May 2022 at Peter MacCallum Cancer Centre were included in this …